S&P affirmed the “BBB” rating on Virginia Mason Medical Center’s series 2007A-C and 1997B bonds, but the ratings will be removed after the sale of the series 2017 bonds.
Additionally, S&P affirmed the “BBB” rating on VMMC’s series 2013 taxable bonds.
“The rating reflects our opinion of Virginia Mason’s strong enterprise profile characterized by widely regarded tertiary capacity and lean management operating philosophy, a large employed physician group and an excellent regional patient draw,” Martin Arrick, an S&P Global Ratings credit analyst, said.
The affirmations are based on S&P’s prediction that the medical center will see improvements in cash flow and stable balance sheet metrics.
The outlook is stable, reflecting S&P’s expectation that VMMC will be able to stabilize its financial profile after a large HMO contract expiration with Group Health Cooperative and merger with Yakima (Wash.) Memorial Medical Center.
More articles on healthcare finance:
Moody’s analyzes financial risks of EMR implementation: 6 findings
Montana family sues air ambulance company after receiving $109k bill
MaineGeneral adds primary care physicians to help shore up finances
Moody’s analyzes financial risks of EMR implementation: 6 findings
Montana family sues air ambulance company after receiving $109k bill
MaineGeneral adds primary care physicians to help shore up finances
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
